PubMed Health⌕ Search

Biomedical subjects

M Konstantinova

Publications and source records attributed to M Konstantinova.

16 recordsLinked to original sources

Clinical and laboratory characteristics of type I (insulin dependent) diabetes mellitus at presentation among Bulgarian children.

Clinical and laboratory data of 1248 newly diagnosed diabetic children at the time of diagnosis were analysed. All children were admitted to the University Children's Hospital in Sofia, 45.9% before first their insulin injection. Symptoms preceding the diagnosis and laboratory data (plasma glucose and ketonuria) were analysed, respectively for 1100 and 1022 children. Blood pH (mainly arterialized) was available in 558 ketonuria positive children and in other 82 acidotic breathing was reported. Mother's education was noted in the 1226 hospital records. Among the children with known urinanalysis 13.5% were without ketonuria (148 patients), 12 of them with fasting blood glucose < or = 6.4 mmol/1 (115 mg/dl). Eighteen-point-two percent of all children were hospitalized in a state of severe ketoacidosis (blood pH < or = 7.2 or reported acidotic breathing). The average duration of thirst and polyuria was 28 +/- 33 days. Ketonuria negative children with plasma glucose < or = 6.4 mmol/l showed a significantly shorter period of symptoms, compared to those with plasma glucose > 6.4 mmol/1 (17 +/- 25 vs. 25 +/- 31 days; P = 0.0991). The cases with severe ketoacidosis, compared to those with mild ketoacidosis (blood pH 7.21 - 7.34) showed shorter period of symptoms too (P = 0.0658). Moderate positive relation existed between the age at diagnosis and duration of symptoms (chi 2 = 43.28, D.F. = 8, P = 0.0000). The percentage of severe ketoacidosis is higher in the younger age groups. Febrile illness, preceding the start of the symptoms was more common in the groups with shorter duration of symptoms (up to 1 month), but did not change the proportion of severe ketoacidosis. No significant difference was found between the level of mother's education and duration of the symptoms before diagnosis (P = 0.9782). We conclude that the level of metabolic disturbances at the diagnosis of IDDM among children was not influenced by the duration of the preceding symptoms. The severity of clinical picture was possibly dependent on the degree of insulinopenia, i.e. the rate of beta-cell destruction. Clinical heterogeneity was possibly dependent on genetical heterogeneity related to HLA class II genes.

Adolescent↗

A cold spot of IDDM incidence in Europe. Macedonia.

OBJECTIVE: To determine, for the first time, the incidence of IDDM among children 0-15 yr of age in Macedonia, the south republic of former Yugoslavia, and to compare these rates with those from neighboring countries. RESEARCH DESIGN AND METHODS: Children < 15 yr of age, with IDDM diagnosed between January 1985 and December 1991, were registered using the criteria established for the WHO Multinational Project for Childhood Diabetes. The primary source of case ascertainment consisted of clinical records from the University Pediatric Clinic in Skopje, the capital of Macedonia. The secondary source consisted of records for insulin supplies from the pharmacy in Skopje and from 15 local hospitals. RESULTS: During 1985-1991, 112 children < 15 yr of age were diagnosed with IDDM in Macedonia. The completeness of case ascertainment was 96.6%. The age-adjusted IDDM incidence rate was very low, only 2.45/100,000 per yr. No significant sex difference in incidence was observed. The highest incidence rate occurred in the 10- to 15-yr age-group. No temporal trends were observed. CONCLUSIONS: The incidence of IDDM in Macedonia is the lowest in Europe and among the lowest reported for Caucasian populations. However, the descriptive epidemiology is similar to that for high incidence populations. Further etiological studies are required to evaluate potential reasons for the very low incidence of IDDM in Macedonia.

Adolescent↗

[Pharmachem's salazopyrine in rheumatoid arthritis].

35 patients with classical form of rheumatoid arthritis were treated with Salazopyrin N "Pharmachim" prepared with the basic substance of the firm "AB-Uppsala"--Sweden. Side effects were seen in 9 patients and in 3 of them the treatment had to be discontinued. After a six months course of treatment remission was found in 18 patients (51%), in 8 patients (22.8%) the result was considered "good" with reduction of the inflammatory activity and in the remaining 5 patients there was little or no effect. The results coincide with those of other authors and support the data for the beneficial action of Salazopyrin N as a basic means in the treatment of rheumatoid arthritis. They also prove that the Bulgarian drug Salazopyrin N is of good quality and can be successfully used in the treatment of rheumatoid arthritis.

Adult↗